RBX2660 (microbiota suspension)

BIOLOGICAL2 trials

Sponsors

Rebiotix Inc.

Conditions

Enterocolitis Clostridium Difficile RecurrentRecurrent Clostridium Difficile Infection

Phase 2

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

CompletedNCT01925417

Rebiotix Inc.Recurrent Clostridium Difficile Infection

Start: 2013-08-31End: 2014-07-31Updated: 2019-11-13

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

CompletedNCT02299570

Rebiotix Inc.Enterocolitis Clostridium Difficile Recurrent

Start: 2014-12-31End: 2018-01-31Updated: 2021-01-15

Related Papers

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.

2026-06-12

Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent <i>Clostridioides difficile</i> infection from five prospective clinical trials: an update.

2025-11-12

Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.

2024-09-016 citations

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

Infectious Diseases and Therapy2022-12-2144 citations

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

2022-10-26197 citations

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.

2021-02-1663 citations

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.

2020-08-3146 citations

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

Clinical Infectious Diseases2018-03-28133 citations

Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent<i>Clostridium difficile</i>Infection: Results of the PUNCH CD Study

Clinical Infectious Diseases2015-11-12188 citations